ArticlePharmacoEconomics2022

Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers.

Jakub P Hlávka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.